Does Glucosamine Cause Dementia? Who the Warning Is For

A single question is driving the glucosamine headlines this autumn: does glucosamine cause dementia? It started with a paper in Nature Metabolism and a university press release, and by the time the story reached the morning shows it had become a flat warning that the joint supplement in millions of medicine cabinets speeds up Alzheimer’s.

The real finding is narrower than that, and who it applies to matters more than the number everyone is repeating. Read the study instead of the coverage and two things come into focus. The risk showed up only in people who already had a memory diagnosis, and a larger study of healthy adults pointed the other way.

---

What Is Glucosamine?

Glucosamine is an amino sugar your body makes on its own and uses to build and repair cartilage, the smooth tissue that cushions a joint. As a supplement it is one of the top sellers on the shelf, taken mostly by older adults for knee and hip osteoarthritis. Most of it is manufactured from the shells of shellfish, and it comes in two salt forms, sulfate and hydrochloride, a distinction that decides whether it does much for your joints in the first place. It sits in the same drawer as the collagen peptides people take for aging joints, and until this year it carried the same reputation: probably helps a bit, very unlikely to hurt.

The new worry is not about joints at all. It is about what happens when that amino sugar reaches the brain, and specifically a brain that already carries the early changes of Alzheimer’s disease.

---

The Science: Does Glucosamine Cause Dementia, or Just Track the People Who Take It?

Three studies decide the honest answer, and they only look contradictory until you notice they studied different people. One is the paper behind the scare. One reran the question and found the signal dissolving. One, larger and older, found glucosamine users doing better, not worse.

---

The study behind the headline

The alarm comes from a single 2026 paper, and it has two halves that deserve to be kept apart.

• The Evidence: In mice bred to develop Alzheimer’s pathology, a two week course of glucosamine at a dose equivalent to a human supplement raised a specific kind of sugar tagging on brain proteins, called N-glycosylation, and the animals then failed a memory test they had passed before. The telling detail is the control: healthy mice given the same glucosamine showed no rise in that sugar tagging and no memory problem. The human half was a look back through University of Florida Health records from 2012 to 2024, covering 24,481 people with Alzheimer’s or a related dementia and 41,884 with mild cognitive impairment. After adjusting for age, sex, and demographics, glucosamine use was linked to roughly a 25 percent higher risk of death over five years in the dementia group, and a roughly 25 percent higher chance of progressing from mild cognitive impairment to dementia. There was no mortality signal in the earlier stage group.
• Read the study: Hyperglycosylation is a metabolic driver of Alzheimer’s disease

That is a serious piece of work, and the mechanism is plausible. It is also where the headline outran the paper. The human part is a records analysis, which can show that two things travel together but cannot show that one causes the other. The authors did not adjust for osteoarthritis or chronic pain, and the people who take glucosamine are, almost by definition, people with sore joints who differ from everyone else in ways a health record never captures. The healthy mice are the clearest signal in the study: glucosamine did nothing to an unaffected brain. This is the same gap between a result and its press release that runs through the supplement shelf, from the 80 percent plaque reduction that was never in the garlic trial onward.

---

A second look suggested the signal was confounding

If a records analysis cannot separate the supplement from the person, the obvious test is to check what other supplements do in the same data. Someone did.

• The Evidence: A 2026 analysis reran the question in the National Alzheimer’s Coordinating Center cohort and compared glucosamine against the other supplements logged in the same medication fields. Glucosamine again tracked with faster progression from mild cognitive impairment to dementia. So did multivitamins and calcium or vitamin D. Nobody thinks a daily multivitamin accelerates Alzheimer’s, so when it carries the same apparent risk as glucosamine, the most likely explanation is that supplement use is a marker for something else, how closely someone is followed, how sick they already are, rather than a cause. The adjusted mortality signal did not hold up here either.
• Read the study: Comparator supplement patterns qualify the clinical interpretation of an EHR-derived glucosamine signal in Alzheimer’s disease

This one is a preprint, so it has not yet cleared peer review, and it deserves the lighter weight that comes with that. But its logic is hard to wave away. It is the confounding argument made with data instead of hand-waving.

---

A larger cohort pointed the other way

Before this year, the biggest study on glucosamine and the brain found the opposite of a hazard.

• The Evidence: A prospective analysis of the UK Biobank followed a large group of middle aged adults who were free of dementia at the start. Over a median of about nine years, regular glucosamine users had a 16 percent lower rate of all-cause dementia than non-users, a hazard ratio of 0.84 (95 percent confidence interval 0.75 to 0.93), with the same downward direction for Alzheimer’s and vascular dementia.
• Read the study: Association of regular glucosamine use with incident dementia

Read quickly, that looks like a flat contradiction of the Florida result. It is not, because the two studies asked different questions of different people. UK Biobank started with healthy adults and asked whether glucosamine users later developed dementia. The Florida study started with people who already had a diagnosis and asked what happened next. Both are observational, so both carry bias, the healthy-user kind in one direction and the sicker-patient kind in the other. Put together they are coherent: no good evidence that glucosamine starts dementia in a healthy brain, and a worrying signal only in brains already affected.

---

A Practical Guide: How to Use It

If you are taking glucosamine for your joints, the form is the first thing to get right, and it has nothing to do with the dementia story. The osteoarthritis trials that actually found a benefit used crystalline glucosamine sulfate, usually around 1,500 mg a day. Trials of the hydrochloride salt have mostly come back empty. The product here is the sulfate form, which is why it is the one to reach for over a cheaper hydrochloride bottle, and even then the realistic expectation is modest relief for some people, not a cure for a worn joint.

The harder question is whether to take it at all, and that now depends on your situation rather than your knees. For a cognitively healthy adult, nothing in the 2026 research is a reason to stop a supplement that is helping. For someone who already has mild cognitive impairment or a dementia diagnosis, the calculation changes, because that is the exact group where the risk signal appeared and where the joint payoff is least likely to be worth it. If that describes you or a parent, the sensible move is to pause it and raise it with the doctor who manages the memory care.

---

Safety and Advice

Glucosamine has a long track record of being well tolerated, and its common side effects are mild and digestive. A few cautions are worth knowing. Most glucosamine is made from shellfish shells, so anyone with a shellfish allergy should choose a plant-fermented version or skip it, though the allergen risk from the shell is low. There are scattered reports of glucosamine strengthening the blood thinner warfarin, so if you take warfarin, clear it with your prescriber and keep your monitoring on schedule. People with diabetes were long warned it might raise blood sugar; that has largely not held up in trials, but it is reasonable to watch your readings when you start.

Set against all of that is the finding this article is about. If you have a diagnosis of mild cognitive impairment or dementia, treat the memory signal as the deciding factor, not the joint benefit. None of this is a substitute for a conversation with the clinician who knows your history.

---

The Bottom Line

Does glucosamine cause dementia? The evidence does not show that. It shows a risk signal concentrated in people who already carry a memory diagnosis, drawn from a records study that could not rule out confounding, sitting alongside a larger study of healthy adults that found lower dementia rates in glucosamine users and a follow-up that watched the signal fade once other supplements were compared against it.

So the answer splits by who is asking. If your joints are the problem and your memory is fine, this is not a reason to quit, though the sulfate form is the only one worth paying for. If you or someone you care for already has mild cognitive impairment or dementia, the cautious and reasonable move is to stop, because the joint benefit is small and the possible harm lands precisely there. Either way, start by checking which salt your bottle contains, and if a memory diagnosis is in the picture, bring the bottle to the next appointment.

---

This article is for educational purposes only and is not medical advice. Supplements can interact with medications and health conditions, so talk to a qualified healthcare provider before starting anything new.